Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 4
1993 1
1994 1
1995 2
1996 2
1997 10
1998 7
1999 5
2000 8
2001 13
2002 7
2003 9
2004 4
2005 1
2006 4
2007 8
2008 13
2009 7
2010 8
2011 16
2012 15
2013 9
2014 10
2015 13
2016 20
2017 11
2018 4
2019 6
2020 6
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

210 results
Results by year
Filters applied: . Clear all
Page 1
Bispecific antibodies: a mechanistic review of the pipeline.
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Labrijn AF, et al. Among authors: parren pwhi. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. doi: 10.1038/s41573-019-0028-1. Nat Rev Drug Discov. 2019. PMID: 31175342 Review.
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM. Moores SL, et al. Among authors: parren pw. Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23. Cancer Res. 2016. PMID: 27216193 Free article.
Complement is activated by IgG hexamers assembled at the cell surface.
Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW. Diebolder CA, et al. Among authors: parren pw. Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943. Science. 2014. PMID: 24626930 Free PMC article.
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. Lammerts van Bueren JJ, et al. Among authors: parren pw. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. Proc Natl Acad Sci U S A. 2012. PMID: 22431606 Free PMC article. No abstract available.
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, Verploegen S, Labrijn AF, Salcedo T, Schuurman J, Parren PWHI, Breij ECW. Engelberts PJ, et al. Among authors: parren pwhi. EBioMedicine. 2020 Feb;52:102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23. EBioMedicine. 2020. PMID: 31981978 Free PMC article.
Celebrating Antibody Therapeutics.
Parren PWHI, Huston JS. Parren PWHI, et al. Protein Eng Des Sel. 2017 Sep 1;30(9):573. doi: 10.1093/protein/gzx053. Protein Eng Des Sel. 2017. PMID: 29088433 No abstract available.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: parren pw. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Free article. Clinical Trial.
Opening the door to innovation.
Schuurman J, Graus YF, Labrijn AF, Ruuls S, Parren PW. Schuurman J, et al. Among authors: parren pw. MAbs. 2014 Jul-Aug;6(4):812-9. doi: 10.4161/mabs.29004. Epub 2014 Apr 24. MAbs. 2014. PMID: 24784437 Free PMC article. Review.
210 results